Section 4 of 6
Clinical evidence
170 evidence topics · 21 sources
Study summaries
COMPANION-002
Objective
Registered purpose of the trial
Objective stated in the trial design publication
“COMPANION-002 is a multicenter, randomized, phase II/III study evaluating the efficacy and safety of CTX-009 in combination with paclitaxel as second-line treatment for patients with advanced or metastatic BTC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Sponsor-stated purpose and regulatory intent
Location and study date
Study dates and status: registry record
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2023-01-09” |
| Primary completion (estimated) | “2027-08-31” |
| Study completion (estimated) | “2027-08-31” |
| Enrollment (actual) | “168” |
| Recruitment status | “Active, not recruiting” |
| Last update posted | “2026-09-02” |
Study design
Registered design details
| Design feature | Registry record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “Single (Outcomes Assessor)” |
Blinded independent central review of the primary endpoint
Randomization ratio and stratification factors
“Patients are randomized to a 2:1 ratio, and crossover is allowed to the experimental arm at the time of progression in the control arm for patients that continue to meet eligibility criteria. Stratification factors include stage (locally advanced vs metastatic), anatomic subtype of the primary tumor (intrahepatic cholangiocarcinoma vs other) and ECOG performance status (0 or 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Crossover from the control arm
Regulatory origin of the randomized design
Eligibility criteria
Key inclusion criteria: registry record
Exclusion of participants eligible for an approved targeted therapy
Cardiovascular, hemorrhagic, and gastrointestinal exclusions relevant to angiogenesis inhibition
Treatment
Dosing of both arms as reported by the sponsor
Registered intervention schedule
| Intervention | Registry description |
|---|---|
| CTX-009 | “IV infusion on day 1 and 14 of every 28 day cycle” |
| Paclitaxel | “IV infusion on day 1, 8, and 15 of every 28 day cycle” |
Adverse event grading and safety follow-up
“Safety will be monitored throughout the study and for 30 days after the end of treatment. Adverse events will be assessed as defined by the National Cancer Institute Common Terminology Criteria for Adverse Events, version 5.0.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using objective response rate as the primary endpoint
Registered primary outcome measure
Registered secondary outcome measures
Endpoint definitions in the trial design publication, including the quality-of-life instrument
“The primary end point is ORR per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) by independent central review (ICR). The secondary end points are progression free survival, duration of response, overall survival, disease control rate, safety and quality of life measured with EORTC QLQ-C30.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Response-rate signal from the preceding phase 2 study that motivated the endpoint
Low response rate of available second-line regimens against which the endpoint was sized
Statistical analysis description
Number of participants (Planned and analyzed)
Event threshold triggering the time-to-event analyses
Description of analysis sets
Crossover-adjusted overall survival analysis and its assumptions
Prespecified status of the crossover analyses
Results
Participant disposition
Crossover from the control arm and total exposure to tovecimig
Participants not evaluable for response
Treatment discontinuation, withdrawal, and follow-up counts
“Between April 2023 and August 2024, 210 patients were screened and 168 randomized to receive tovecimig plus paclitaxel (n=111) or paclitaxel alone (n=57). In total, 108 and 53 patients, respectively, received treatment” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Thirty-one (31) patients (54.4%) in the paclitaxel arm crossed over and received tovecimig plus paclitaxel. Overall, 84.5% (n=142/168) of patients received tovecimig plus paclitaxel.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 66 (39.3%) patients received subsequent therapy after study completion, of which 60.6% received a fluorouracil-based regimen.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Balance of baseline characteristics between arms
Baseline demographics and disease characteristics, n (%) unless stated
| Characteristic | Tovecimig plus paclitaxel (n=111) | Paclitaxel (n=57) |
|---|---|---|
| Median age, years | “65.0” | “63.0” |
| Male | “53 (47.7)” | “24 (42.1)” |
| Female | “58 (52.3)” | “33 (57.9)” |
| Asian | “17 (15.3)” | “10 (17.5)” |
| White | “84 (75.7)” | “40 (70.2)” |
| African American | “4 (3.6)” | “6 (10.5)” |
| Unknown or other race | “6 (5.4)” | “1 (1.8)” |
| Intrahepatic primary location | “62 (55.9)” | “30 (52.6)” |
| Other primary location (extrahepatic, gallbladder, ampullary) | “49 (44.1)” | “27 (47.4)” |
| ECOG performance status 0 | “53 (47.7)” | “27 (47.4)” |
| ECOG performance status 1 | “58 (52.3)” | “30 (52.6)” |
| Locally advanced disease | “12 (10.8)” | “5 (8.8)” |
| Metastatic disease | “99 (89.2)” | “52 (91.2)” |
Efficacy results
Primary endpoint: objective response rate as first reported
Primary endpoint: objective response rate in the final analysis
Primary and key secondary endpoints in the peer-reviewed publication
“168 patients were randomized 2:1 to tovecimig+paclitaxel (n=111) or paclitaxel alone (n=57). Tovecimig+paclitaxel significantly improved BICR-assessed ORR (18.0% vs 5.3%; P=.0228) and PFS (4.7 vs 2.6 months; hazard ratio [HR], 0.44; P<.0001).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Overall, 142 patients (85%) received tovecimig; no difference in OS was observed (HR, 1.05; P=.779).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tovecimig combined with paclitaxel significantly improved ORR and PFS versus paclitaxel alone as second-line therapy for patients with BTC.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Progression-free and overall survival with confidence intervals in the peer-reviewed publication
“Median BICR-assessed PFS was 4.7 months (95% CI, 3.9–5.6) with tovecimig plus paclitaxel versus 2.6 months (95% CI, 1.9–3.6) with paclitaxel alone, corresponding to a 56% reduction in the risk of progression or death” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median OS was 8.9 months (95% CI, 7.0–11.2)” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“with tovecimig plus paclitaxel versus 9.4 months (95% CI, 6.5–13.5) in patients randomized to paclitaxel alone” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Crossover-adjusted overall survival by two-stage estimation
“A post-hoc exploratory analysis of OS to correct for crossover using the Two-Stage Estimation revealed an HR of 0.85 (95% CI, 0.59–1.26” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This method estimates the treatment effect on OS if crossover had not occurred.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Prespecified intrahepatic cholangiocarcinoma subgroup
“In the subgroup of patients with intrahepatic cholangiocarcinoma, defined according to a prespecified anatomic subsite stratification factor, treatment effects were consistent with those observed in the overall ITT population, with an ORR of 15.3% versus 0%” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“median PFS of 5.1 months versus 3.0 months (HR, 0.32; 95% CI, 0.18–0.57” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“the study was not powered to evaluate efficacy within individual anatomical or molecular subgroups.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Best overall response by blinded independent central review, intent-to-treat population
| Best overall response | Tovecimig plus paclitaxel (n=111) | Paclitaxel (n=57) |
|---|---|---|
| Overall response rate (complete plus partial response) | “19 (17.1%)” | “3 (5.3%)” |
| Complete response | “1 (0.9%)” | “0 (0.0%)” |
| Partial response | “18 (16.2%)” | “3 (5.3%)” |
| Stable disease | “49 (44.1%)” | “19 (33.3%)” |
| Non-complete response / non-progressive disease | “9 (8.1%)” | “2 (3.5%)” |
| Progressive disease | “18 (16.2%)” | “24 (42.1%)” |
| Not evaluable | “16 (14.4%)” | “9 (15.8%)” |
Key secondary endpoint: progression-free survival
Key secondary endpoint: overall survival in the intent-to-treat population
Efficacy summary with hazard ratios and two-sided p values
| Endpoint | Tovecimig plus paclitaxel (n=111) | Paclitaxel (n=57) | Hazard ratio | Two-sided p value |
|---|---|---|---|---|
| Overall response rate | “19 (17.1%)” | “3 (5.3%)” | Not reported | “p=0.031” |
| Progression-free survival, months | “4.7” | “2.6” | “0.44” | “p<0.0001” |
| Overall survival, intent-to-treat, months | “8.9” | “9.4” | “1.05” | “p=0.78” |
| Overall survival, crossover-adjusted by rank-preserving structural failure time, months | “8.9” | “9.4” | “1.13” | “p=0.65” |
Prespecified secondary analysis of progression-free survival before and after crossover
Post hoc analysis of overall survival within the control arm
Post hoc analysis of progression-free survival within the control arm
Post hoc pooled overall survival of all participants who received tovecimig
Crossover analyses in the peer-reviewed publication
“Among the 31 patients who crossed over to the tovecimig plus paclitaxel arm, the ORR was 6.5%” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Median PFS improved from 1.9 months on paclitaxel alone (95% CI, 1.7–3.0) (PFS) to 3.5 months on tovecimig plus paclitaxel following crossover (95% CI, 1.7– 9.7) (post-progression PFS; HR, 0.40; 95% CI, 0.2–0.7” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“This analysis should be interpreted with caution due to the lack of adjustment for intrapatient correlation.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“In an additional exploratory post hoc subgroup analysis, patients who received tovecimig plus paclitaxel at any time during the study (n=142) had a median OS of 9.9 months (95% CI, 7.5– 11.7).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
Quality of life as a prespecified secondary endpoint
Reported quality-of-life or patient-reported outcome results
Safety results
Treatment-emergent adverse events reported in at least 20% of participants, n (%)
| Adverse event | Tovecimig plus paclitaxel (n=108), any grade | Tovecimig plus paclitaxel (n=108), grade 3 or higher | Paclitaxel (n=53), any grade | Paclitaxel (n=53), grade 3 or higher |
|---|---|---|---|---|
| Hypertension | “75 (69)” | “56 (52)” | “10 (19)” | “3 (6)” |
| Fatigue | “72 (67)” | “16 (15)” | “24 (45)” | “3 (6)” |
| Neutropenia | “59 (55)” | “40 (37)” | “20 (38)” | “14 (26)” |
| Diarrhea | “51 (47)” | “6 (6)” | “15 (28)” | “1 (2)” |
| Anemia | “48 (44)” | “23 (21)” | “17 (32)” | “5 (9)” |
| Decreased appetite | “44 (41)” | “2 (2)” | “11 (21)” | “-” |
| Nausea | “43 (40)” | “2 (2)” | “17 (32)” | “-” |
| Proteinuria | “37 (34)” | “3 (3)” | “5 (9)” | “-” |
| Vomiting | “36 (33)” | “1 (1)” | “13 (25)” | “1 (2)” |
| Abdominal pain | “35 (32)” | “9 (8)” | “13 (25)” | “4 (8)” |
| Dyspnea | “32 (30)” | “5 (5)” | “13 (25)” | “-” |
| Epistaxis | “32 (30)” | “-” | “4 (8)” | “-” |
| Alopecia | “32 (30)” | “-” | “28 (53)” | “-” |
| Thrombocytopenia | “33 (31)” | “7 (7)” | “6 (11)” | “-” |
| Peripheral edema | “35 (32)” | “-” | “7 (13)” | “-” |
| Peripheral neuropathy | “29 (27)” | “2 (2)” | “13 (25)” | “1 (2)” |
| Constipation | “30 (28)” | “-” | “8 (15)” | “-” |
| Headache | “25 (23)” | “-” | “7 (13)” | “-” |
| Arthralgia | “25 (23)” | “-” | “6 (11)” | “-” |
Consistency of the safety profile across data cuts
Deaths, serious adverse events, and discontinuations due to adverse events
“TEAEs leading to overall treatment discontinuation occurred in 27.8% and 11.3% of patients, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Tovecimig required dose modifications in 78.7% of patients and was discontinued because of AEs in 30.6% of patients. TEAEs leading to death were reported in six patients (5.6%) in the combination arm and one patient (1.9%) in the paclitaxel-alone arm.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“two deaths were considered treatment-related, one involving sepsis and renal failure and one involving septic shock.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Treatment-emergent adverse event categories, all-treated population, n (%)
Study limitations
Summary
COMPANION-002 randomized 168 participants 2:1 and met its primary endpoint of objective response rate, reported first as 17.1% (19 of 111) versus 5.3% (3 of 57) with p=0.031 and updated in the final analysis to 18.0% (20 of 111) with p=0.0228 after one participant initially classified as non-complete response and non-progressive disease was adjudicated a partial response by blinded independent central review. The trial was powered to detect a 23% absolute difference in response rate with 90% power and a two-sided alpha of 0.05, so the observed difference of about 12 percentage points is smaller than the effect the sample size was planned around, and the planned sample size of approximately 150 was exceeded by the 168 actually randomized. The complete dataset was published in the Journal of Clinical Oncology in October 2026 and presented at the 2026 European Society for Medical Oncology Congress; the earlier results came from sponsor announcements and a corporate presentation filed with the U.S. Securities and Exchange Commission. The publication reports the post-crossover progression-free survival comparison with a hazard ratio of 0.40 and the pooled median overall survival of the 142 tovecimig-treated participants as 9.9 months, where the sponsor announcements reported 0.36 and 9.8 months.
Overall survival did not reach statistical significance. Median overall survival was 8.9 months with tovecimig plus paclitaxel versus 9.4 months in the control arm, hazard ratio 1.05 and p=0.78. The sponsor attributes this to crossover: 31 of 57 control participants (54%) crossed over after centrally confirmed progression, so 142 of 168 participants (85%) received tovecimig, and the control arm is not a tovecimig-naive comparator for survival. The prespecified rank-preserving structural failure time adjustment gave 8.9 versus 9.4 months with a hazard ratio of 1.13 and p=0.65, and the sponsor states that the assumptions of that method were not met and that its results here are largely uninterpretable. The crossover comparisons that show benefit, the 12.8 versus 6.1 month survival difference between crossover and non-crossover control participants and the pooled 9.8 month survival of all tovecimig-treated participants, are post hoc subset analyses of non-randomized groups; the same analysis showed crossover participants had progressed faster on paclitaxel alone, with median progression-free survival of 1.9 versus 3.6 months, indicating the two control subgroups differed.
The trial was conducted at 34 sites, all in the United States, and eligibility excluded participants who could receive an approved molecularly targeted therapy after first-line chemotherapy, so the results apply to the population without an actionable alteration rather than to all second-line biliary tract cancer. The registry record and the sponsor announcements describe different tovecimig schedules, day 1 and day 14 in the registry against days 1 and 15 in the press releases. The publication reports a median duration of response of 21.4 weeks, serious adverse events in 65.7% versus 41.5% of treated participants, discontinuation of study treatment for treatment-emergent adverse events in 27.8% versus 11.3%, and treatment-emergent adverse events leading to death in 5.6% versus 1.9%. The EORTC QLQ-C30 quality-of-life endpoint listed in the design publication has not been reported, and the publication states that quality-of-life analyses will be reported separately. The authors state that the study was not powered to evaluate efficacy within individual anatomical or molecular subgroups, and a post hoc two-stage crossover adjustment gave an overall survival hazard ratio of 0.85 (95% CI 0.59 to 1.26). Safety was reported for 108 and 53 participants rather than the 111 and 57 randomized, and grade 3 or higher hypertension occurred in 52% of the tovecimig arm against 6% of the control arm.
ABL001-P1bC phase 1b/2 study of CTX-009 with irinotecan or paclitaxel
Objective
Origin of the biliary tract cancer cohort
“A phase Ib study conducted in South Korea, evaluated CTX-009 in combination with either irinotecan or paclitaxel in patients with metastatic or advanced solid tumors. Two out of three patients with cholangiocarcinoma who received CTX-009 in combination with paclitaxel achieved confirmed PRs. This observation in the phase Ib study led to the addition of a phase II cohort that enrolled patients with BTC who were treated in the second- or third-line setting.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study dates and status: registry record
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2020-06-22” |
| Primary completion (actual) | “2024-01-08” |
| Study completion (actual) | “2025-01-09” |
| Enrollment (actual) | “41” |
| Recruitment status | “Terminated” |
| Reason stopped | “Change of Development Plan” |
Data cut-off and follow-up of the reported phase 2 analysis
Study design
Registered design details
| Design feature | Registry record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “Non-Randomized” |
| Interventional model | “Parallel Assignment” |
| Masking | “None (Open Label)” |
Phase 1b and phase 2 populations
Single-arm phase 2 design as reported at the congress
Simon two-stage adaptive design and the decision not to run the second stage
Eligibility criteria
Key inclusion criteria: registry record
Key exclusion criteria: registry record
Treatment
Registered interventions
| Intervention | Registry description |
|---|---|
| CTX-009 (ABL001) | “CTX-009 (ABL001) will be administered biweekly.” |
| Paclitaxel | “Paclitaxel will be administered weekly.” |
| Irinotecan | “Irinotecan will be administered biweekly.” |
Study outcomes
Rationale for using objective response rate as the primary endpoint
Registered primary outcome measures
Primary and secondary objectives as reported at the congress
Statistical analysis description
Number of participants (Planned and analyzed)
Total enrollment across both phases
Participants analyzed in the phase 2 biliary tract cancer cohort
“A total of 24 patients were enrolled: nine (37%) with intrahepatic cholangiocarcinoma, three (13%) with extrahepatic cholangiocarcinoma, seven (29%) with gallbladder cancer and five (21%) with ampullary carcinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Participants analyzed in the phase 1b cholangiocarcinoma subset
Description of analysis sets
Basis of the reported response assessment
Formal definition of the efficacy and safety analysis sets
No evidence found.
Results
Participant disposition
Participants remaining on treatment at the data cut-off
Discontinuation due to adverse events
Baseline characteristics
Line of therapy and anatomic subtype
“A total of 24 patients were enrolled: nine (37%) with intrahepatic cholangiocarcinoma, three (13%) with extrahepatic cholangiocarcinoma, seven (29%) with gallbladder cancer and five (21%) with ampullary carcinoma.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Age, sex, and performance status at baseline
No evidence found.
Efficacy results
Response and survival outcomes as reported at the congress
Response and survival outcomes as summarized in the trial design publication
“The primary end point of the phase II study was overall response rate (ORR) and the ORR was 37.5% (n = 9/24 patients). Among 11 patients treated in the second-line, the ORR was 63.6% (n = 7/11) versus 15% (n = 2/13) among patients treated in the third-line setting. The median duration of response was 6.9 months, and responses were seen in patients with all anatomic subtypes of BTC, including ampullary cancer. The median progression-free survival was 9.4 months and the survival rate at 1 year was 53%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment-related adverse events as reported at the congress
Treatment-emergent adverse events regardless of relationship, as reported by the sponsor
Study limitations
Summary
The phase 2 biliary tract cancer cohort was single-arm, open-label, and enrolled 24 participants at four sites, all in South Korea, so its 37.5% response rate has no concurrent control and was not estimated in a United States population. Responses were assessed by investigator review in the reported analysis rather than by the independent radiology review named as the registered primary outcome measure. Participants had received one or two prior systemic therapies, and the response rate differed markedly by line of therapy, 63.6% in the second line against 15.4% in the third line, so the estimate depends on the mix of lines enrolled. Two sources report different durations of response for the same cohort, a median of 9.4 months in the congress abstract and 6.9 months in the trial design publication, and median overall survival had not been reached at the August 12, 2022 data cut-off with a median follow-up of 11.8 months. Toxicity was frequent: treatment-related adverse events of grade 3 or higher were reported in 75% of participants, including one grade 5 pneumonia, and six participants (25.0%) discontinued because of a treatment-emergent adverse event. The study was terminated for a change of development plan, and the second stage of the Simon two-stage design was not conducted after the sponsor agreed with the U.S. Food and Drug Administration to move directly to a randomized trial, so the cohort was never expanded to the planned size. No baseline demographic table, quality-of-life outcome, or peer-reviewed full report of the cohort has been published.
COMPANION-003
Objective
Location and study date
Study dates and status: registry record
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2022-12-08” |
| Primary completion (actual) | “2025-05-15” |
| Study completion (actual) | “2025-05-15” |
| Enrollment (actual) | “49” |
| Results first posted | “2026-07-28” |
Region of enrollment
Study design
Registered design details
| Design feature | Registry record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
Eligibility criteria
Prior bevacizumab exposure of the enrolled population
Treatment
Study outcomes
Rationale for using overall response rate as the primary endpoint
Registered primary outcome measure
Response-rate benchmark used to interpret the endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Planned and actual enrollment and the stage 1 stopping decision
Description of analysis sets
Population analyzed for the posted outcome measures
Population analyzed for duration of response
Results
Participant disposition
Baseline characteristics
Age and region
| Characteristic | CTX-009 10 mg/kg (n=49) |
|---|---|
| Mean age, years (standard deviation) | “58.6(11.54)” |
| Region of enrollment | “United States 49” |
Efficacy results
Response and survival as reported by the sponsor in the response-evaluable population
Posted time-to-event outcomes in all treated participants
| Outcome measure | Median | Interquartile range | Participants analyzed |
|---|---|---|---|
| Duration of response, weeks | “14.4” | “(13.3 to 15.4)” | “2” |
| Progression-free survival, months | “3.9” | “(1.8 to 5.8)” | “49” |
| Overall survival, months | “10.2” | “(5.3 to 17.8)” | “49” |
Association between DLL4 expression and outcome
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Overall adverse event rates
| Category | Affected / at risk (%) |
|---|---|
| All-cause mortality | “34/49 (69.39%)” |
| Serious adverse events | “14/49 (28.57%)” |
| Other, non-serious adverse events | “47/49 (95.92%)” |
Most frequent non-serious adverse events
| Adverse event | Affected / at risk (%) |
|---|---|
| Hypertension | “22/49 (44.90%)” |
| Proteinuria | “18/49 (36.73%)” |
| Nausea | “14/49 (28.57%)” |
| Fatigue | “13/49 (26.53%)” |
| Weight decreased | “11/49 (22.45%)” |
| Headache | “10/49 (20.41%)” |
| Cardiac failure | “9/49 (18.37%)” |
| Diarrhoea | “8/49 (16.33%)” |
| Decreased appetite | “8/49 (16.33%)” |
Nature of the reported cardiac failure events
Sponsor characterization of the safety profile
Study limitations
Summary
COMPANION-003 studied tovecimig as monotherapy in metastatic colorectal cancer, not in biliary tract cancer, so it informs the safety profile and the DLL4 biomarker hypothesis rather than the indication. It was open-label and single-arm, enrolled 49 participants at sites in the United States only, and stopped after stage 1 because the protocol-defined criterion for progression to stage 2 was not met. Only 2 of 40 response-evaluable participants responded, and duration of response was estimated from those 2 participants, so the 14.4 week median is not a stable estimate. The sponsor reports response and disease control against a denominator of 40 response-evaluable participants while the registry posts outcomes against all 49 enrolled, so the two sets of figures are not interchangeable. The registry record specifies RECIST version 1.0 for the response definitions although the drug program otherwise uses RECIST version 1.1. No participant completed the study, 34 of 49 participants died, 7 withdrew, and 7 ended participation when the sponsor terminated the study, so follow-up was truncated. The comparison with anti-VEGF agents showing 1.0% to 1.5% response rates is a cross-trial comparison, and the statement that participants with DLL4-positive tumors did better is an unadjusted subgroup observation. Quality-of-life outcomes were not collected, and the results are available from the registry and sponsor filings rather than a peer-reviewed publication.
2024-0279 first-line CTX-009 with gemcitabine, cisplatin, and durvalumab
Objective
Primary and secondary objectives
Location and study date
Study dates, status, and site: registry record
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2025-01-22” |
| Primary completion (estimated) | “2027-05-01” |
| Enrollment (estimated) | “50” |
| Recruitment status | “Recruiting” |
| Last update posted | “2026-09-09” |
Study design
Sponsor description of the investigator-sponsored trial
Eligibility criteria
Key inclusion criteria: registry record
| Criterion | Quoted registry text |
|---|---|
| Age | “Age ≥ 18 years.” |
| Diagnosis and prior therapy | “Histologically or cytologically confirmed (outside pathology reports will be accepted) unresectable advanced, metastatic, or recurrent BTC at the time of enrollment that has not been previously treated in the metastatic setting.” |
| Performance status | “ECOG performance status ≤2” |
Treatment
Registered interventions
Doses and schedules of each agent
No evidence found.
Study outcomes
Rationale for using incidence of adverse events as the primary endpoint
Registered primary outcome measure
Justification of the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
This is an investigator-sponsored phase 1/2 trial at a single institution with an estimated enrollment of 50 participants and no randomization or comparator arm. Its primary outcome measures are the incidence of adverse events and 6-month progression-free survival, so it is designed to establish tolerability and a maximum tolerated dose of CTX-009 added to gemcitabine, cisplatin, and durvalumab rather than to demonstrate efficacy. The population is first-line and previously untreated in the metastatic setting, which is a different population from the second-line population of COMPANION-002. Estimated primary completion is May 1, 2027, and no results had been posted or presented as of the September 9, 2026 registry update. The registry record does not state the doses or schedules of the four agents.
Tovecimig plus FOLFIRI in second line metastatic colorectal cancer
Objective
Location and study date
Study dates, status, and site: registry record
| Milestone | Registry record |
|---|---|
| Study start (estimated) | “2026-08-31” |
| Primary completion (estimated) | “2030-08-31” |
| Enrollment (estimated) | “25” |
| Recruitment status | “Not yet recruiting” |
| Last update posted | “2026-06-23” |
Study design
Single-group open-label phase 2 design
Sponsor description of the investigator-sponsored trial
Eligibility criteria
Key inclusion criteria: registry record
| Criterion | Quoted registry text |
|---|---|
| Diagnosis | “Histologically or cytologically confirmed CRC.” |
| Prior therapy | “Patient must have advanced or metastatic disease, and have progressed on one line of standard of care therapy in the advanced/metastatic setting” |
| Measurable disease | “Measurable disease per RECIST 1.1.” |
| Age | “At least 18 years of age.” |
| Performance status | “ECOG performance status ≤ 2” |
Treatment
Study outcomes
Rationale for using overall response rate as the primary endpoint
Registered primary outcome measure
Justification of the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
Registered performance-status outcome measure
Reported quality-of-life results
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
This is an investigator-sponsored, open-label, single-group phase 2 trial at one institution with an estimated enrollment of 25 participants, in metastatic colorectal cancer rather than biliary tract cancer. As of the June 23, 2026 registry update it was not yet recruiting, with an estimated start of August 31, 2026 and estimated primary completion of August 31, 2030, so no results exist. The single-group design without a comparator means the primary outcome of overall response rate cannot be attributed to the addition of tovecimig to FOLFIRI, and the planned quality-of-life measure is change in Eastern Cooperative Oncology Group performance status rather than a patient-reported instrument.
CTX-009 with or without CTX-471 for recurrent glioblastoma
Objective
Location and study date
Study dates, status, and site: registry record
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2026-06-16” |
| Primary completion (estimated) | “2029-06-30” |
| Enrollment (estimated) | “54” |
| Recruitment status | “Recruiting” |
| Last update posted | “2026-06-22” |
Study design
Sequential enrollment of the monotherapy and combination arms
Eligibility criteria
Key inclusion criteria: registry record
Treatment
Study outcomes
Rationale for using overall survival rate at 12 months as the primary endpoint
Registered primary outcome measures
Justification of the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
This is an investigator-sponsored phase 1b/2 trial at one institution in recurrent glioblastoma, not biliary tract cancer, with an estimated enrollment of 54 participants. The two arms enroll sequentially rather than concurrently, so the monotherapy and combination arms are not randomized against each other. The trial began on June 16, 2026 with estimated primary completion on June 30, 2029, and no results had been posted as of the June 22, 2026 registry update. The phase 2 primary outcome is the 12-month overall survival rate in each arm without a control group, so it will be interpreted against external benchmarks.
NOV150101-101 First-in-Human phase 1 dose escalation and expansion
Objective
Location and study date
Study dates and status: registry record
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2017-09-18” |
| Primary completion (actual) | “2021-03-02” |
| Study completion (actual) | “2021-03-02” |
| Enrollment (actual) | “45” |
| Recruitment status | “Completed” |
Study sites
“This study was conducted at three different sites in the Republic of Korea (Seoul National University Hospital Bundang, Samsung Medical Center, and Asan Medical center) and was approved by the Institutional Review Board (IRB) of Seoul National University Hospital Bundang, the IRB of Samsung Medical Center, and the IRB of Asan Medical Center.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Registered design details
| Design feature | Registry record |
|---|---|
| Primary purpose | “Treatment” |
| Allocation | “N/A” |
| Interventional model | “Single Group Assignment” |
| Masking | “None (Open Label)” |
| Phase | “Phase 1” |
Dose levels, starting dose, and administration schedule
“The initial dose of 0.3 mg/kg was determined based on the no observed adverse effect level (NOAEL) 10 mg/kg in the monkey model, converted to human equivalent dose with the safety factor of 10.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After confirming safety in the dose escalation cohort, additional patients were recruited in 7.5, 10, 12.5, and 15 mg/kg dose groups, which were the target dose levels to show clinically meaningful efficacy based on the results of the preclinical study (data on file).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Key inclusion criteria: registry record
| Criterion | Quoted registry text |
|---|---|
| Age and diagnosis | “≥19 year old patients with histologically or cytologically confirmed metastatic or unresectable advanced solid tumors” |
| Measurable disease | “Lesions measured by tumor markers or by CT/MRI must be evaluable based on response evaluation criteria in solid tumors (RECIST) version 1.1.” |
| Life expectancy | “Life expectancy ≥12 weeks” |
| Performance status | “ECOG performance status ≤2” |
Exclusion of prior anti-DLL4 therapy and clinically significant cardiovascular disease
“Patients who had clinically significant cardiovascular disease, including pulmonary hypertension and myocardial infarction, hypersensitivity to humanized/human mAb, or who previously received anti‐DLL4 antibody were excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Route, infusion duration, and dosing interval
“Patients received an intravenous infusion of ABL001/CTX‐009 diluted in 0.9% normal saline (250 mL) over 1 h. ABL001/CTX‐009 was administered in a 2‐week cycle, with the exception of the second dose, which had a 3‐week interval. Administration continued until unacceptable toxicity or disease progression was identified according to RECIST version 1.1.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Registered intervention
Study outcomes
Rationale for using dose-limiting toxicity as the primary endpoint
Registered primary outcome measure
Justification of the primary endpoint
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Participants contributing to the population pharmacokinetic analysis
“From the dose escalation cohort, a total of 712 PK samples from 31 patients were included for population PK model development (0.3 mg/kg = 4, 1 mg/kg = 4, 2.5 mg/kg = 3, 5 mg/kg = 4, 7.5 mg/kg = 3, 10 mg/kg = 3, 12 mg/kg = 3, 15 mg/kg = 4, and 17.5 mg/kg = 3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Response-evaluable population
Results
Participant disposition
No evidence found.
Baseline characteristics
Prior therapy, performance status, and tumor types
Age and body weight in the dose escalation cohort
| Characteristic | Dose escalation cohort (N = 31) |
|---|---|
| Mean age, years (standard deviation) | “53.5 (12.4)”View highlighted excerpt for this quote |
| Age range, years | “25, 81”View highlighted excerpt for this quote |
| Mean weight, kg (standard deviation) | “64.2 (16.4)”View highlighted excerpt for this quote |
Biliary tract cancer subset at baseline
No evidence found.
Efficacy results
Responses, dose levels at which they occurred, and DLL4 expression
Response and disease control at the recommended phase 2 doses
Efficacy in the biliary tract cancer subset of the phase 1 monotherapy study
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Dose-limiting toxicities and treatment-emergent adverse events
Study limitations
Summary
The first-in-human study was open-label, single-arm, and enrolled 45 participants at sites in South Korea only, so it supports dose selection rather than efficacy. No maximum tolerated dose was reached because no dose-limiting toxicities were observed across nine dose levels from 0.3 to 17.5 mg/kg, so the recommended phase 2 doses of 10 mg/kg and 12.5 mg/kg rest on activity and pharmacokinetics rather than on toxicity. Participants were heavily pretreated, with a median of four prior lines, and the tumor types enrolled were predominantly gastric (n=19) and colorectal (n=18) cancer; no biliary tract cancer subset result is reported, so the study provides no direct evidence for the indication. Two sources give different response-evaluable denominators for the same analysis, 39 in the congress abstract and 40 in the trial design publication, and the response rate of 18.8% at the recommended phase 2 doses is based on 3 responses among 16 participants. Only three confirmed partial responses occurred, all in participants whose archived tumor tissue showed high DLL4 expression, a finding from a small biomarker subset that was not prospectively tested. The study has been reported only as a congress abstract and, for pharmacokinetics, as a modeling paper using data from 31 dose escalation participants; no full clinical report has been published, and participant disposition and quality-of-life outcomes are not available.